Literature DB >> 32522714

Biomimetic tolerogenic artificial antigen presenting cells for regulatory T cell induction.

Kelly R Rhodes1, Randall A Meyer1, Justin Wang1, Stephany Y Tzeng1, Jordan J Green2.   

Abstract

Regulatory T cell (Treg)-based therapeutics are receiving increased attention for their potential to treat autoimmune disease and prevent transplant rejection. Adoptively transferred Tregs have shown promise in early clinical trials, but cell-based therapies are expensive and complex to implement, and "off-the-shelf" alternatives are needed. Here, we investigate the potential of artificial antigen presenting cells (aAPCs) fabricated from a blend of negatively charged biodegradable polymer (poly(lactic-co-glycolic acid), PLGA) and cationic biodegradable polymer (poly(beta-amino ester), PBAE) with incorporation of extracellular protein signals 1 and 2 and a soluble released signal 3 to convert naïve T cells to induced Foxp3+ Treg-like suppressor cells (iTregs) both in vitro and in vivo in a biomimetic manner. The addition of PBAE to the aAPC core increased the conjugation efficiency of signal proteins to the particle surface and resulted in enhanced ability to bind to naïve T cells and induce iTregs with potent suppressive function. Furthermore, PLGA/PBAE tolerogenic aAPCs (TolAPCs) supported the loading and sustained release of signal 3 cytokine TGF-β. A single dose of TolAPCs administered intravenously to C57BL/6 J mice resulted in an increased percentage of Foxp3+ cells in the lymph nodes. Thus, PLGA/PBAE TolAPCs show potential as an "off-the-shelf" biomimetic material for tolerance induction. STATEMENT OF SIGNIFICANCE: Regulatory T cells (Tregs) are promising for basic research and translational medicine as they can induce tolerance and have the potential to treat autoimmune diseases such as type 1 diabetes and multiple sclerosis. As cell-based therapies are expensive and difficult to manufacture and implement, non-cellular methods of engineering endogenous Tregs are needed. The research reported here describes a new type of biomimetic particle, tolerogenic artificial antigen presenting cells (TolAPCs) fabricated from a blend of negatively charged biodegradable polymer, poly(lactic-co-glycolic acid), and positively charged biodegradable polymer, poly(beta-amino ester), along with key biomolecular signals: extracellularly presented protein signals 1 and 2 and a soluble released signal 3. These TolAPCs bind to naïve T cells and induce Foxp3+ Treg-like suppressor cells with potent suppressive function. In both in vitro and in vivo studies, it is shown that this non-cellular approach is useful to induce tolerance.
Copyright © 2020 Acta Materialia Inc. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Artificial antigen presenting cell; Bioengineering; Immunoengineering; Immunotherapy; Regulatory T cell; Tolerance

Mesh:

Year:  2020        PMID: 32522714      PMCID: PMC7365762          DOI: 10.1016/j.actbio.2020.06.004

Source DB:  PubMed          Journal:  Acta Biomater        ISSN: 1742-7061            Impact factor:   8.947


  37 in total

1.  Role of target geometry in phagocytosis.

Authors:  Julie A Champion; Samir Mitragotri
Journal:  Proc Natl Acad Sci U S A       Date:  2006-03-20       Impact factor: 11.205

2.  Reversal of autoimmunity by boosting memory-like autoregulatory T cells.

Authors:  Sue Tsai; Afshin Shameli; Jun Yamanouchi; Xavier Clemente-Casares; Jinguo Wang; Pau Serra; Yang Yang; Zdravka Medarova; Anna Moore; Pere Santamaria
Journal:  Immunity       Date:  2010-04-08       Impact factor: 31.745

Review 3.  Nanoscale artificial antigen presenting cells for cancer immunotherapy.

Authors:  Kelly R Rhodes; Jordan J Green
Journal:  Mol Immunol       Date:  2018-03-07       Impact factor: 4.407

4.  Engineering an "infectious" T(reg) biomimetic through chemoselective tethering of TGF-β1 to PEG brush surfaces.

Authors:  E Y Yang; J P Kronenfeld; K M Gattás-Asfura; A L Bayer; C L Stabler
Journal:  Biomaterials       Date:  2015-07-14       Impact factor: 12.479

Review 5.  How regulatory T cells work.

Authors:  Dario A A Vignali; Lauren W Collison; Creg J Workman
Journal:  Nat Rev Immunol       Date:  2008-07       Impact factor: 53.106

6.  Reprogramming the Local Lymph Node Microenvironment Promotes Tolerance that Is Systemic and Antigen Specific.

Authors:  Lisa H Tostanoski; Yu-Chieh Chiu; Joshua M Gammon; Thomas Simon; James I Andorko; Jonathan S Bromberg; Christopher M Jewell
Journal:  Cell Rep       Date:  2016-09-13       Impact factor: 9.423

7.  First-in-man clinical results of the treatment of patients with graft versus host disease with human ex vivo expanded CD4+CD25+CD127- T regulatory cells.

Authors:  Piotr Trzonkowski; Maria Bieniaszewska; Jolanta Juścińska; Anita Dobyszuk; Adam Krzystyniak; Natalia Marek; Jolanta Myśliwska; Andrzej Hellmann
Journal:  Clin Immunol       Date:  2009-06-25       Impact factor: 3.969

8.  Epigenetic control of the foxp3 locus in regulatory T cells.

Authors:  Stefan Floess; Jennifer Freyer; Christiane Siewert; Udo Baron; Sven Olek; Julia Polansky; Kerstin Schlawe; Hyun-Dong Chang; Tobias Bopp; Edgar Schmitt; Stefan Klein-Hessling; Edgar Serfling; Alf Hamann; Jochen Huehn
Journal:  PLoS Biol       Date:  2007-02       Impact factor: 8.029

9.  In vitro-expanded antigen-specific regulatory T cells suppress autoimmune diabetes.

Authors:  Qizhi Tang; Kammi J Henriksen; Mingying Bi; Erik B Finger; Greg Szot; Jianqin Ye; Emma L Masteller; Hugh McDevitt; Mark Bonyhadi; Jeffrey A Bluestone
Journal:  J Exp Med       Date:  2004-06-07       Impact factor: 14.307

10.  Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression.

Authors:  Silvia Deaglio; Karen M Dwyer; Wenda Gao; David Friedman; Anny Usheva; Anna Erat; Jiang-Fan Chen; Keiichii Enjyoji; Joel Linden; Mohamed Oukka; Vijay K Kuchroo; Terry B Strom; Simon C Robson
Journal:  J Exp Med       Date:  2007-05-14       Impact factor: 14.307

View more
  5 in total

Review 1.  Nanoparticles for generating antigen-specific T cells for immunotherapy.

Authors:  Savannah E Est-Witte; Natalie K Livingston; Mary O Omotoso; Jordan J Green; Jonathan P Schneck
Journal:  Semin Immunol       Date:  2021-12-23       Impact factor: 11.130

Review 2.  Local delivery strategies to restore immune homeostasis in the context of inflammation.

Authors:  Elizabeth R Bentley; Steven R Little
Journal:  Adv Drug Deliv Rev       Date:  2021-09-13       Impact factor: 15.470

Review 3.  Tolerance, immunosuppression, and immune modulation: impacts on lung allograft survival.

Authors:  Hailey M Shepherd; Jason M Gauthier; Daniel Kreisel
Journal:  Curr Opin Organ Transplant       Date:  2021-06-01       Impact factor: 2.269

4.  Phosphorylation inhibition of protein-tyrosine phosphatase 1B tyrosine-152 induces bone regeneration coupled with angiogenesis for bone tissue engineering.

Authors:  Yong Tang; Keyu Luo; Yin Chen; Yueqi Chen; Rui Zhou; Can Chen; Jiulin Tan; Moyuan Deng; Qijie Dai; Xueke Yu; Jian Liu; Chengmin Zhang; Wenjie Wu; Jianzhong Xu; Shiwu Dong; Fei Luo
Journal:  Bioact Mater       Date:  2021-01-07

Review 5.  Vaccine formulations in clinical development for the prevention of severe acute respiratory syndrome coronavirus 2 infection.

Authors:  Cole J Batty; Mark T Heise; Eric M Bachelder; Kristy M Ainslie
Journal:  Adv Drug Deliv Rev       Date:  2020-12-13       Impact factor: 17.873

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.